Financial Performance - Revenue for the year ended September 30, 2025, was $18,670,684, a decrease of 21.3% from $23,844,556 in 2024 and a 36.8% decline from $29,522,353 in 2023[47]. - Gross profit for 2025 was $3,878,821, down 45.5% from $7,110,009 in 2024 and a 56.2% decrease from $8,840,027 in 2023[47]. - The net loss for 2025 was $2,049,431, compared to a net income of $345,248 in 2024, marking a significant decline[47]. - Basic loss per share for 2025 was $(0.72), a sharp drop from earnings of $4.17 per share in 2024[47]. - The weighted average ordinary shares outstanding increased dramatically to 2,755,232 in 2025 from 95,513 in 2024[47]. Assets and Liabilities - As of September 30, 2025, total assets increased to $85,185,615 from $61,765,432 in 2024, representing a growth of approximately 37.8%[46]. - Current assets rose to $45,760,451 in 2025, up from $39,793,857 in 2024, indicating an increase of about 15.4%[46]. - Total equity increased to $57,997,739 in 2025, compared to $44,349,539 in 2024, reflecting a growth of approximately 30.9%[46]. - Current liabilities grew to $26,308,460 in 2025 from $16,445,832 in 2024, marking an increase of about 60.5%[46]. - Total liabilities rose to $27,187,876 in 2025, up from $17,415,893 in 2024, which is an increase of approximately 56.5%[46]. Cash Management and Dividends - The company has not made any dividends or distributions to shareholders and intends to retain future earnings for business expansion[36]. - As of September 30, 2025, the accumulated profits available for dividends were $16,626,207, compared to $18,741,685 as of September 30, 2024, indicating a decrease of approximately 11.9% year-over-year[112]. - The withholding tax rate applicable to dividends payable by Chinese companies to non-PRC-resident enterprises is 10%, which may be reduced to 5% under certain conditions for Hong Kong enterprises[114]. - The company relies on dividends from its PRC subsidiary for cash requirements, and any limitations on these distributions could materially affect growth and investment capabilities[112]. Regulatory Environment - The company is subject to the Holding Foreign Companies Accountable Act, which could impact its ability to trade on U.S. exchanges if its auditor is not inspected by the PCAOB for two consecutive years[28]. - The company has obtained all material licenses and permits from PRC government authorities for its operations, but future compliance remains uncertain[39]. - The company is subject to the complex and rapidly evolving laws and regulations in China, which may impact its operations and the value of its ordinary shares[77]. - Recent regulations require companies controlling personal information of over one million users to undergo cybersecurity reviews before listing in foreign markets, which could affect the company's ability to offer securities[80]. - The company faces uncertainties regarding future regulatory approvals for overseas listings, which could significantly limit its ability to offer securities[88]. Competition and Market Conditions - The company faces increased competition from firms with greater capital resources, which could impact market share and profitability[65]. - The Chinese economy has shown uneven growth, with a slowing rate since 2012, which could adversely affect the company's demand for services[93]. - Disruptions at the company's factories or suppliers could materially affect business operations, especially due to natural disasters or regulatory compliance issues[98]. Internal Controls and Governance - The company has identified several material weaknesses in its internal control over financial reporting as of September 30, 2025, which could impair the accuracy of financial statements[170]. - Remedial measures have been initiated, including hiring qualified accounting personnel and implementing training programs to strengthen financial reporting[172]. - The company's corporate governance practices differ significantly from those required for U.S. domestic issuers, potentially affording less protection to shareholders[164]. - The company is a foreign private issuer and is exempt from certain provisions applicable to U.S. domestic public companies, which may limit the information available to shareholders[166]. Future Plans and Investments - The company plans to invest in expanding its direct sales force and distribution channels to meet increasing product demand[60]. - The company estimates a capital need of approximately $30 million for expansion, including investments in research and development and marketing[66]. - The company plans to use the net proceeds from the public offering for sales network expansion, research and development, production capacity expansion, and working capital[195]. Shareholder Rights and Market Activity - Shareholders have limited rights under Cayman Islands law to inspect corporate records, which may hinder their ability to obtain necessary information for shareholder actions[162]. - The trading price of the company's shares on the Nasdaq Capital Market may fluctuate significantly due to various factors, including market conditions and company performance[153]. - The company does not expect to pay dividends in the foreseeable future, relying instead on price appreciation for returns on investment[159].

Core Viewpoint - Bonduelle Group has achieved B Corp certification, highlighting its commitment to sustainability and a plant-rich diet, which aligns with its mission to positively impact both society and the environment [2][3][17]. Group 1: B Corp Certification - The B Corp certification is part of Bonduelle's "Transform to Win" plan, emphasizing sustainability as a core aspect of its business model [5]. - B Corp certification evaluates companies based on five pillars: governance, employees, communities, customers, and the environment, promoting continuous improvement [7][15]. - Bonduelle's CEO, Xavier Unkovic, stated that B Corp certification enhances transparency and strengthens commitments to stakeholders, fostering a more responsible business model [8][10]. Group 2: Company Performance and Goals - Bonduelle generated revenue of €2.2 billion for the 2024-2025 financial year, reflecting its strong market position [17]. - The company has trained 11,000 chefs in plant-rich cuisine over the past three years, indicating its commitment to promoting healthier eating habits [18]. - 98% of Bonduelle's products have a Nutri-Score of A or B, showcasing the nutritional quality of its offerings [18]. Group 3: Environmental and Social Impact - 59% of Bonduelle's partner farmers practice regenerative agriculture, with a goal to increase this to 80% by 2030, demonstrating a commitment to sustainable farming practices [18]. - 73% of irrigable farmland is equipped with systems to limit irrigation, with plans to increase this to 90% by 2030, reflecting efforts to conserve water resources [18]. - 100% of Bonduelle's sites are involved in local initiatives that have a positive impact, reinforcing its community engagement [18].

12月18日，由陕西长安先导产业创新中心、西安天美生物科技股份有限公司及国声智库共同主办的 BON&先导天然成分与生物制造联合实验室揭牌仪式在西安创业园瞪羚谷举行。 BON&先导天然成分与生物制造联合实验室由长安先导产业创新中心与天美生物联合共建，作为全国首 家聚焦天然成分与生物制造领域的专业联合实验室，此次揭牌仪式标志着该领域产学研协同创新迈出重 要一步。双方将围绕天然成分与生物制造领域开展研发合作。 该实验室将采用更环保、更高效的生物制造技术，从天然物质里挖掘新的活性成分，通过微生物"工 厂"实现可持续生产。依托天美生物在功能物质研发领域的四大平台（活性研究、制造、优化、检测评 估），以及长安先导中心的平台和人才资源优势，搭建起"从分子发现到精准干预"的全链条研发体系， 不管是功能性食品还是个人护理产品，都可能用上这里的创新技术，让生物制造技术真正落地到生活 里。 责编：马宁 审核：姚启明 西安天美生物科技股份有限公司作为一家在西安创业园成长起来的企业，公司自2006年创立以来，始终 深耕天然活性成分领域，并于2021年在美国纳斯达克挂牌上市（股票代码BON），是首家美股上市的 中国提取物供应商，已成为国 ...

Core Insights - Bon Natural Life Limited has launched a new health-focused kombucha-inspired product and entered a strategic collaboration with Shaanxi Qingshengyuan Health Industry Co., Ltd. for a total contract value of $12 million over 24 months [1] - The new product is designed to meet the growing consumer demand for tea-based products that are efficient, pure, and scientifically formulated, featuring higher levels of tea pigments compared to similar products [2] - The kombucha market is rapidly growing, particularly among younger consumers, driven by interest in natural ingredients and health benefits [3] Company Developments - The strategic sales agreement with Qingshengyuan will enable BON to distribute its high-tea-pigment products across Greater China, enhancing its market presence in the functional product industry [1][7] - The CEO of BON emphasized that this collaboration aims to increase market awareness of their ingredient technologies and broaden product reach among targeted consumer groups, supporting future revenue and earnings growth [7] Industry Trends - Tea pigments, which are natural and water-soluble, are gaining traction as alternatives to synthetic additives in the food and beverage industry, aligning with consumer preferences for natural ingredients [4][5] - The market for tea-pigment-based ingredients is projected to reach approximately $1 billion in the coming years, indicating significant growth potential [6]

Core Insights - Bon Natural Life Limited has entered a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co. Ltd. for a total contract value of US$26 million over 36 months, focusing on the distribution of second-generation tea pigment-based digestive health products in Greater China [1]. Group 1: Product and Market Insights - Tea pigments, derived from tea, are recognized for their benefits in lipid regulation, glycemic control, antioxidant function, and gastrointestinal support, with a market opportunity projected to exceed US$1 billion in the coming years [2]. - The latest tea pigment product from Bon Natural Life has shown a more than 200% increase in digestive health activity compared to first-generation formulations, indicating significant advancements in product efficacy [4]. Group 2: Strategic Developments - The partnership with Huahai Keyuan is expected to enhance Bon Natural Life's competitive strengths and innovation in tea pigment technology, facilitating expansion into the premium digestive health market [5]. - The company plans to introduce its second-generation tea pigment product portfolio to global markets, aiming for meaningful revenue and earnings growth over time [5].

Core Points - The Combined General Meeting of Bonduelle is scheduled for December 4, 2025, at 5 p.m. at the company's administrative headquarters in Villeneuve d'Ascq, France [4] - Prior notice including the agenda and draft resolutions was published in the Bulletin des Annonces Légales Obligatoires (BALO) on October 24, 2025, with further notices to be published on November 17, 2025 [5] - Preparatory documents for the Annual General Meeting are available online and can be downloaded from the company's website [6] - The General Meeting will be broadcast live on the company's website, and a recording will be available afterward [7] - Shareholders have the right to request documents related to the meeting and inspect them at the company's administrative headquarters [9]

Core Insights - The Bonduelle Group reported sales of 519.8 million euros for Quarter 1 of FY 2025-2026, reflecting a decline of -0.5% on a like-for-like basis and -2.1% on reported figures compared to the same period last fiscal year [3][5][10] - The company continues to demonstrate resilience in a challenging economic environment, aligning with its current operating income objectives announced previously [4][13] Sales Performance - Total consolidated sales for Quarter 1 FY 2025-2026 were 519.8 million euros, down from 530.8 million euros in the same quarter of the previous year, marking a -2.1% decrease [5][7] - Sales in the Europe Zone, which constitutes 62.6% of total business activity, decreased by -1.9% on reported figures and -2.0% on a like-for-like basis due to weak consumer trends and unfavorable weather conditions [8] - The Non-Europe Zone, representing 37.4% of business activity, experienced a growth of +1.9% on a like-for-like basis but reported a decline of -2.3% [10] Segment Analysis - Canned products saw a sales increase of 1.7% to 244.6 million euros, while frozen products grew by 0.4% to 68.3 million euros [7] - Fresh processed products experienced a significant decline of -6.9%, with sales dropping to 206.9 million euros [7] Future Outlook - The company anticipates that innovations launched across various product segments will enhance commercial activity in the upcoming quarters [9] - Despite the current challenges in the consumer environment, Bonduelle reaffirms its objective for current operating income for FY 2025-2026 [13]

Core Points - The Bonduelle Group has filed its 2024-2025 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on October 16, 2025 [3] - The document is publicly available and can be accessed on the company's website and the AMF website [3] - A free English translation of the document will be available on the company's website by November 15, 2025 [4] Document Contents - The Universal Registration Document includes the 2024-2025 Annual Financial Report, the management report with the Sustainability Report, the Corporate Governance Report, and details of the stock buyback program [5]

Core Insights - The Bonduelle Group has successfully met its revenue and profitability objectives for the fiscal year 2024-2025 as part of its "Transform to win" transformation plan, driven by improved performance in the U.S., reorganization in Europe, and enhanced operational efficiency [3][4][30] Financial Performance - Total sales for FY 2024-2025 amounted to 2,203.8 million euros, reflecting a decrease of -0.8% on a like-for-like basis and -0.9% on reported figures compared to FY 2023-2024 [5][6] - Current operating income was reported at 83.8 million euros, a slight increase of +0.2% from the previous fiscal year, with a current operating margin of 3.8% [6][15] - Net income from continuing operations reached 19.7 million euros, a significant recovery from -108.1 million euros in the previous fiscal year [22][24] Business Activity - Sales in the Europe Zone totaled 1,354.5 million euros, down -3.9% on reported figures, while the Non-Europe Zone saw an increase of +4.4% in sales, totaling 849.3 million euros [8][12] - The canned segment experienced a decline of -4.4%, while the fresh processed segment grew by +4.4% [9][10] - North America showed a return to growth with +4.8% on a like-for-like basis, driven by the success of complete meal solutions [13] Operational Developments - The company initiated the disposal of its packaged salad business in Germany and France, which were structurally loss-making, allowing Bonduelle to focus on higher value-added activities [26][27][28] - Marketing investments increased by 8% to support the growth of branded products [21] Financial Situation - As of June 30, 2025, net debt stood at 571.2 million euros, with a leverage ratio of 3.38 [25] - The company plans to propose a dividend of 0.25 euros per share during the Annual General Meeting on December 4, 2025 [29] Outlook - For FY 2025-2026, Bonduelle aims to recover current operating profitability to 90 million euros, supported by growth in branded activities and improved operational performance [30][31]

Core Insights - Bon Natural Life Limited has entered a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co. Ltd. for a total contract value of US$18 million over 24 months, focusing on the distribution of its second-generation Apple Series health products in Greater China [1] - The second-generation Apple Series utilizes advanced low-temperature extraction technology, achieving 80% higher bioactivity compared to its predecessor, enhancing the efficacy of active ingredient extraction [2] - The incorporation of apple polyphenols into protein supplements offers clinically validated benefits, including improved lipid metabolism and enhanced body composition, positioning the product for significant growth potential in the health and wellness market [3] Market Validation and Performance - Early market validation shows comparable apple polyphenol blends generating over $40 million in monthly sales, indicating a strong consumer demand for scientifically validated nutraceutical products [4] - The company’s management is confident in achieving strong market performance due to the competitive advantages of its second-generation formulation [4] - The Chairman and CEO of BON emphasized the company's capability to lead in the metabolic health segment, expecting significant revenue and profit growth across nutraceutical and functional food markets [5]